BC Week In Review | Oct 12, 2015
Clinical News

ENV515: Phase IIa data

An open-label, U.S. Phase IIa trial in 21 patients with bilateral ocular hypertension or early primary open-angle glaucoma showed that a single dose of ENV515 met the primary endpoint of reducing diurnal IOP at day...
BC Extra | Oct 7, 2015
Clinical News

Envisia's ENV515 matches Travatan Z in glaucoma study

Envisia Therapeutics Inc. (Research Triangle Park, N.C.) said ENV515 met the primary endpoint in a Phase IIa trial to treat glaucoma. The extended-release formulation of travoprost significantly reduced intraocular pressure (IOP) in the dose-ranging study,...
BioCentury | Jul 21, 2014
Emerging Company Profile

Envisia: Ophthalmic nanotechnology

Envisia Therapeutics Inc. is using its PRINT microparticle formulation technology to develop sustained-release, implantable versions of approved drugs for glaucoma and age-related macular edema. The products could solve compliance problems with existing therapeutics and could...
BC Week In Review | Nov 18, 2013
Company News

Envisia Therapeutics, Liquidia ophthalmic news

Liquidia spun out its ophthalmology programs into Envisia. The newco's lead program is ENV515 , an extended-release formulation of an undisclosed prostaglandin analogue in preclinical development to reduce intraocular pressure (IOP) in glaucoma patients. The newco...
BC Extra | Nov 13, 2013
Financial News

Liquidia spins out ophthalmic newco Envisia

Liquidia Technologies Inc. (Research Triangle Park, N.C.) spun out its ophthalmology programs into Envisia Therapeutics Inc. (Research Triangle Park, N.C.), which secured $25 million in a series A round from Canaan Partners; New Enterprise Associates;...
Items per page:
1 - 5 of 5